Cambridge-based BioTech company, Mestag Therapeutics, has been granted a Transforming Cancer Therapeutics award of £1.5 million from Innovate UK’s Cancer Therapeutics programme. Innovate UK is investing £12 million to boost the development of next-generation immunotherapies for cancer. The money provided to Mestag Therapeutics will facilitate the fast development of its innovative MST-0300 antibody, which is designed to induce tertiary lymphoid structures (TLS) in solid tumours to improve outcomes for cancer patients. Hard-to-treat cancer models show effective anti-tumour results from Mestag data presented recently at the American Association of Cancer Research conference.
CEO Susan Hill commented, “The presence of TLS in tumours is emerging as a key driver of improved treatment outcomes in cancer patients, and our MST-0300 programme holds important therapeutic promise. Leveraging the dynamic UK BioTech ecosystem, Innovate UK funding will enable us to advance MST-0300 rapidly to solid tumour patients who urgently need new treatment options.”
